BMS-986036

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

NAFLD

Conditions

NAFLD, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis

Trial Timeline

Sep 11, 2018 → Jun 24, 2019

NCT ID

NCT03674476

About BMS-986036

BMS-986036 is a phase 1 stage product being developed by Bristol Myers Squibb for NAFLD. The current trial status is completed. This product is registered under clinical trial identifier NCT03674476. Target conditions include NAFLD, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04649710	Phase 1	Withdrawn	Jun 21, 2021	Sep 22, 2021	Healthy Participants
NCT04634149	Phase 1	Completed	Nov 23, 2020	Jun 2, 2022	Moderate Liver Impairment
NCT04493567	Phase 1	Completed	Jul 29, 2020	Jun 11, 2021	Healthy Participants
NCT03674476	Phase 1	Completed	Sep 11, 2018	Jun 24, 2019	NAFLD
NCT03486899	Phase 2	Completed	Jun 19, 2018	Aug 17, 2021	Liver Fibrosis
NCT03486912	Phase 2	Completed	Jun 12, 2018	Sep 14, 2021	Hepatic Cirrhosis
NCT03611101	Pre-clinical	Completed	May 4, 2018	Nov 10, 2021	NASH - Nonalcoholic Steatohepatitis
NCT03445208	Phase 1	Completed	Feb 14, 2018	May 2, 2018	Hepatic Cirrhosis

Competing Products

15 competing products in NAFLD

See all competitors

Product	Company	Stage	Hype Score
Lanifibranor	Inventiva	Phase 2	47
Saroglitazar	Zydus Lifesciences	Approved	85
AZD4076 + Placebo	AstraZeneca	Phase 1	33
AZ compound	AstraZeneca	Phase 2	52
Placebo + Omega-3 carboxylic acid + Fenofibrate 200mg + Placebo	AstraZeneca	Phase 2	52
LCQ908 + placebo	Novartis	Phase 2	52
Placebo + RO5093151	Roche	Phase 1	33
Semaglutide Pen Injector + Placebo	Novo Nordisk	Phase 2	51
Ketohexokinase inhibition	Pfizer	Phase 2	51
PF-05221304 Monotherapy + PF-06865571 Monotherapy + Placebo + PF-05221304 and PF-06865571 Combination	Pfizer	Phase 2	51
ALN-PNP + Placebo	Regeneron Pharmaceuticals	Phase 1	32
Legalon® 140 mg	Viatris	Pre-clinical	20
Elobixibat + Placebo oral tablet	Ipsen	Phase 2	49
Placebo + ISIS 703802 40 mg + ISIS 703802 80 mg + ISIS 703802 20 mg	Ionis Pharmaceuticals	Phase 2	49
EDP 305 + Placebo	Enanta Pharmaceuticals	Phase 1	25

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved